Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.
Built on over a decade of AI-driven data collection combined with expert human curation, CiteAb's database contains 16 million research tools and their use in 40 million publications, covering antibodies, proteins, models, kits and more. As of 2026, instrument data is also included. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster.
The new Image Search tool is designed to enable researchers to rapidly investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides easy access to 850,000 cropped experimental images -- covering 610,000 proteins, 5,000 diseases, and 160,000 cell lines -- linked directly to publications and the reagents used.
Together, the research tools in CiteAb Explore are intended to help researchers cut time spent navigating fragmented data sources, reduce R&D waste, and achieve more reproducible results.
The CiteAb Explore platform is freely accessible to academics, with a paid subscription model for commercial users.
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
CrossBridge Bio to be acquired by Eli Lilly
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Hoth Therapeutics reports positive HT-VA CRADA data
Kelun-Biotech reports Phase II study results for sac-TMT at 2026 SGO
Genmab reports positive safety data for Rina-S combination in ovarian cancer
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer
Almirall expands supercomputing and AI collaboration with Barcelona Supercomputing Center
Qlucore launches AI-based AML test
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
Haisco Pharmaceutical signs global pain‑drug licensing deal with AbbVie
AnBogen Therapeutics to present Imofinostat (ABT-301) breakthroughs at AACR 2026